IrelandIreland

Ireland backs biotech

20.03.2012

While on a trip to strengthen economic ties between Ireland and California, Ireland's minister for jobs, enterprise and innovation, Richard Bruton, revealed on 15 March that two Irish government organisations have provided roughly one tenth of a life science-focused venture capital fund. The Sofinnova Ventures Partners VIII from Sofinnova Ventures Menlo Park, California, is worth $440 million. One organisation, Enterprise Ireland, invested $25 million from its €250 million Innovation Fund Ireland. Enterprise Ireland's aim is to help Irish companies in international markets. In return for the investment, Sofinnova is expected to establish operations in Ireland. The first efforts by the Innovation Fund Ireland to attract VC firms stem back to 2010. Back then it solicited the first proposals from VC firms that promised to invest in Irish companies. The other organisation is the Irish National Pensions Reserve Fund (NPRF). It contributed half the amount, $12.5 million, to the Sofinnova fund. So far, three other investments by the NPRF are known: with Polaris Ventures, Draper Fisher Jurvetson Network Funds (DFJ) and DFJ Esprit. The 8th fund raised by Sofinnova has a life science focus only - with an emphasis on Phase 2 and 3 drug development and was closed on 17 October 2011. With $440 million, it again continues to grow (2007 Sofinnova Ventures VII: $375 million). Already included in Sofinnova's portfolio is one Irish biotech firm. Amarin is a clinical-stage biopharmaceutical company from Dublin. It focuses on improving the treatment of cardiovascular disease. Bruton stressed the importance of VC funds for mentoring young companies: "That is why the Programme for Government tries to support the development of a more dynamic venture capital industry in Ireland by seeking to attract top tier venture capitalists to invest in Ireland."

IrelandIreland

14.10.2009

Dublin – Amarin Corporation plc today announced it has entered into an agreement with a number of investors for a $70 million private placement. The placement of units for $70 million consists of $66.4 million in cash proceeds...

IrelandIreland

19.09.2009

Dublin – The Republic of Ireland has amended its patent law to bring it into line with the rest of Europe and make its domestic patenting system more straightforward. The government said increased levels of research in Ireland in...

IrelandIreland

10.08.2009

Dublin - The honeymoon between Elan and Biogen has been over for a long time, now the marriage of the Irish biotech company and their US partner lies in ruins. The Elan Corporation has filed suit against Biogen Idec Inc. In the...

IrelandIreland

12.07.2009

Dublin – Ireland is focussing on expanding productivity in the upstream processing of biological drugs. Science Minister Conor Lenihan has announced EUR2.3m in funding for the next 3 years aimed at delivering more efficient and...

IrelandIreland

07.07.2009

Dublin/New Brunswick – Pharma giant Johnson &Johnson will buy all assets of Irish Elan Pharmaceuticals’ Alzheimer’s Immunotherapy Programme (AIP) through a newly formed company. The new company will pay $1 billion for an 18.4%...

IrelandIreland

17.06.2009

Dublin – Trinity College of Dublin's Institute of Molecular Medicine has opened Ireland´s first next generation DNA sequencing facility. The platform, built upon the current market-leading “Illumina Genome Analyzer II“ platform,...

IrelandIreland

14.06.2009

Dublin – Trinity College Dublin spin-out Opsona Therapeutics, a specialist in autoimmune and inflammatory diseases, has announced that the Roche Venture Fund and Enterprise Ireland have committed an additional EUR3.3m to the...

IrelandIreland

22.04.2009

Dublin – Ireland fears growing rates of resistant pneumococcus in the country's hospitals. A recent report by the Health Protection Surveillance Centre (HSPC) shows that 32% of 124 clinical isolates tested were non-susceptible to...

IrelandIreland

31.10.2008

Cork – Ireland is set to lose another 180 pharma jobs after pharmaceutical giant Pfizer announced it had failed to find a buyer for one of its five manufacturing facilities in the country. For the past 18 months, the company has...

IrelandIreland

14.08.2008

Dublin/Zurich – Analyst Ian Hunter of Goodbody Stockbrokers has maintained his “add” rating on Irish Elan Corp Plc. The fair value for the pharma combine has been raised from EUR18 to EUR19. The analyst says that the company has...

Displaying results 21 to 30 out of 49

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-ireland/browse/2/article/ireland-backs-biotech.html

Events

All Events

Stock list

All quotes

TOP

  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%
  • ADDEX3.32 CHF0.00%

FLOP

  • CYTOTOOLS31.45 EUR-0.47%
  • 4SC1.16 EUR0.00%
  • ACTELION110.70 CHF0.00%

TOP

  • SANTHERA94.75 CHF47.8%
  • FORMYCON8.30 EUR19.9%
  • EPIGENOMICS3.61 EUR14.6%

FLOP

  • EVOTEC3.12 EUR-16.8%
  • MEDIGENE3.98 EUR-15.7%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA94.75 CHF2524.7%
  • CO.DON2.71 EUR218.8%
  • PAION2.71 EUR155.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • 4SC1.16 EUR-40.5%
  • MERCK KGAA68.05 EUR-38.7%

No liability assumed, Date: 14.09.2014


Current issue

All issues

Product of the week

Products